Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 23, 2026Indian Journal of DermatologyOpen Access

Effectiveness of Abrocitinib in Cyclosporine-Resistant Atopic Dermatitis: A Real-world Experience from the Indian Subcontinent

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAbhishek DeCalcutta National Medical College and HospitalDCDisha ChakrabortyMayo ClinicSAS. K. Shahriar AhmedCalcutta National Medical College and Hospital

Discussion

Loading...

Member takes

Implication

This prospective case series evaluates abrocitinib’s effectiveness in treating atopic dermatitis in India, suggesting a valuable alternative for resistant cases.

Key Points

  • To evaluate the effectiveness and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis resistant to cyclosporine.
  • Prospective real-world case series design
  • Assessment using Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), and Peak Pruritus Numerical Rating Scale (PP-NRS) at baseline and weeks 2, 4, 8, and 12
  • Mean daily dose of abrocitinib was prescribed and monitored.
  • Mean EASI score decreased significantly from 48.22 at baseline to 6.33 at week 12 (P < 0.0001)
  • IGA scores showed improvement from 4 to 1.22 by week 12
  • Peak Pruritus scores dropped from 8.44 to 2 by week 12, with early significant improvements observed.

Cite This Study

De et al. (2026) studied this question.

synapsesocial.com/papers/69e9b91385696592c86ebfd1https://doi.org/10.4103/ijd.ijd_516_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis2001 · 1,211 citations
  2. 2Current Burden of Atopic Dermatitis in India: A Systematic Literature Review2023 · 33 citations
  3. 3Burden of Disease, Unmet Needs in the Diagnosis and Management of Atopic Dermatitis: An Indian Expert Consensus2021 · 18 citations
  4. 4Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)2024 · 14 citations
  5. 5Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China2025 · 4 citations